



## City Research Online

### City, University of London Institutional Repository

---

**Citation:** Zhang, J. and Baden-Fuller, C. (2010). The Influence of Technological Knowledge Base and Organizational Structure on Technology Collaboration. *Journal Of Management Studies*, 47(4), pp. 679-704. doi: 10.1111/j.1467-6486.2009.00885.x

This is the accepted version of the paper.

This version of the publication may differ from the final published version.

---

**Permanent repository link:** <https://openaccess.city.ac.uk/id/eprint/13998/>

**Link to published version:** <http://dx.doi.org/10.1111/j.1467-6486.2009.00885.x>

**Copyright:** City Research Online aims to make research outputs of City, University of London available to a wider audience. Copyright and Moral Rights remain with the author(s) and/or copyright holders. URLs from City Research Online may be freely distributed and linked to.

**Reuse:** Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

**THE INFLUENCE OF TECHNOLOGICAL KNOWLEDGE BASE AND  
ORGANIZATIONAL STRUCTURE ON TECHNOLOGY COLLABORATION**

**JING ZHANG**

Assistant Professor  
Iowa State University  
Department of Management  
Ames, IA 50011  
United States  
Tel: +1 515 294 7650  
Email: jing@iastate.edu

**CHARLES BADEN-FULLER**

Professor  
City University London  
Cass Business School  
106 Bunhill Row  
London, EC1Y 8TZ  
United Kingdom  
Tel.: +44 20 7040 8652  
E-mail: c.baden-fuller@city.ac.uk

**Acknowledgements:**

We gratefully acknowledge encouragement and helpful comments from the participants of the Knowledge Workshop in Cass Business School, City University London during 2004-2005. We also thank Vincent Mangematin, Marc Anderson, Rudi Durand, Bernard Garrette, Xavier Castañer, Mike Wright and the three anonymous reviewers for their constructive comments. We are also very grateful to Lionel Nesta for sharing the patent data with us. This project is supported by the UK's ESRC under the Evolution of Business Knowledge (EBK) programme, award no: RES 334-25-0016. The early version of this article was presented at the Academy of Management conference 2005.

## THE INFLUENCE OF TECHNOLOGICAL KNOWLEDGE BASE AND ORGANIZATIONAL STRUCTURE ON TECHNOLOGY COLLABORATION

### ABSTRACT

This study investigates how an incumbent company's internal characteristics influence its propensity to form learning alliances. A firm may be reluctant to enter a research alliance when it has deep knowledge in a certain technological field due to concerns about knowledge leakage and the low possibility of being able to learn much from collaboration. On the contrary, when the firm has a broad knowledge base, it may have high propensity to enter alliances due to more self-confidence in its ability to learn fast from partners. In addition, we argue that when a firm concentrates its R&D at a central location, this neutralizes the positive and negative influences of the two knowledge base features on alliance formation. We tested and found support for the hypotheses using a database of 1,550 alliances undertaken by 78 large incumbent pharmaceutical, chemical and agro-food companies active in the biotechnology sector during 1993 to 2002.

### *Keywords:*

Biotechnology, knowledge base, organizational structure, strategic alliance

## INTRODUCTION

Collaborative activity has long been seen as beneficial to technological development (Ettlie & Pavlou, 2006; Quinn, 2000). Alliances allow complementary assets to be exploited (Das & Teng, 2000; Tsang, 2000); but more importantly, alliances provide invaluable opportunities for firms to learn or access new knowledge in a more effective way (Ahuja, 2000; Baum et al., 2000; Dyer & Nobeoka, 2000; Grant & Baden-Fuller, 2004). The latter perspective of organizational learning is particularly useful in explaining research collaboration by large incumbent firms in industries that experience technological revolution (Rothaermel, 2001). For instance, in the biopharmaceutical sector, many incumbent pharmaceutical companies build up their biotechnological knowledge base through working with new biotech firms (NBFs) or universities (Pangarkar, 2009; Rothaermel & Boeker, 2007; Rothaermel & Deeds, 2006).

Past writers have stressed that technology (research) collaboration can also bring dangers. Apart for the obvious danger that the costs of making collaboration outweigh the value of the knowledge, the main concern is competition within cooperative relationships. A firm may enter alliances primarily to learn a partner's know how in order to become a more effective competitor (Hamel, 1991), and hence the partner that is slow in the learning race finds itself in a great disadvantage in either gaining benefits from the collaboration or competing against its winning partner in the market place (Ireland, Hitt & Vaidyanath, 2002; Teece, 1986). This means that research partnerships are not unambiguously welcome.

In unpicking the dimensions of the value equation, some prior studies framed the problem as one of learning about knowledge. There are three major groups of studies examining the relationship between knowledge and alliance formation. The first group has highlighted the

effects of quantity or magnitude of a firm's knowledge base, for instance the number of research pipelines (Higgins & Rodriguez, 2006), on alliance behavior. While some studies have found a positive effect (e.g., Kinder, 2003; Quinn, 2000), some found a negative one (Harrigan, 1985; Pisano, 1990), and some did not find a constant effect at all (e.g., Mol, 2005). The second group has focused on the different types of knowledge to be transferred or created in the learning process, such as tacit versus explicit knowledge (Dhanaraj et al, 2004; Inkpen & Wang, 2006; Nielsen & Nielsen, 2009), ambiguous knowledge (Simonin, 1999), and embedded knowledge (Tsang, 2000). Although these studies have described the learning process, they have not explained why a firm allies with other organizations. The third group has studied the question of who allies with whom by examining the relationships of knowledge features between alliance partners. They have focused on similarity of firms' technological knowledge (e.g., measured by patent cross-citation by Rothaermel and Boeker, 2007) and similarity of firms' knowledge processing methods (e.g., measured by compensation practice by Lane and Lubatkin, 1998). However, thus far "few studies explicitly account for a firm's knowledge *structuration* within organizational boundaries" (George, Kotha and Zheng, 2008: 1451) in alliance formation research. In other words, the literature has paid little attention to the *features of a firm's knowledge base* in its propensity to form alliances. As a result, we still do not have a good understanding of why some firms have more alliances than the others.

To fill this research gap, in this study we compare the value of the two opposing logics – alliances as beneficial or detrimental — by examining two important firm knowledge features: depth and breadth. We propose that when a firm's technological knowledge is deep (Wang & von Tunzelmann, 2000), collaboration may be discouraged, due to the greater risks of knowledge being disclosed and the lower chances of benefiting from learning from partners. However, when

a firm possesses broad knowledge, it may seek for more alliances. There are two reasons: first, broad knowledge may be associated with architectural knowledge, which is hard for the partners to steal (Brusoni et al., 2001); and second, such broadness may increase the firm's absorptive capacity, enhancing the ability to integrate knowledge from its partners into a novel use in new product development (Cohen & Levinthal, 1990).

The technological knowledge of the firm can be categorized along another dimension: whether it is centralized into a single division at a single place or dispersed among many different units in different locations. Previous studies have suggested that organizational structure (centralized or decentralized) can have an impact on firm's search and innovation activities (Ambos et al., 2008; Siggelkow & Levinthal, 2003), especially in turbulent and complex environments (Siggelkow & Rivkin, 2005; Volberda, 1996), and that centralized R&D may generate innovation that has a broader and larger impact on the subsequent technological evolution (Argyres & Silverman, 2004). However, the linkage between R&D organization and alliances has been overlooked.

We know that organizational structure may influence decision making process including external technology collaboration (Fredrickson, 1986); and we also know that alliances are a very powerful and popular tool for search and innovation (Ahuja, 2000; Baum et al., 2000; Dyer & Nobeoka, 2000; Grant & Baden-Fuller, 2004), so we explore in this study whether a firm's alliance behavior could be a very important mechanism through which organizational structure affects firm's search and innovation activities. In our exploration, we not only examine the direct effect of R&D organizational structure on alliance formation; but more importantly, we focus on the moderating role of R&D structure on the effects of a firm's knowledge features on its

propensity to form alliances. We argue that when a firm's R&D is centrally located, the more efficient communication between labs and tighter control by headquarters may reduce concerns about problems such as knowledge leakage and innovation appropriation associated with deep knowledge bases, thus tending to alleviate the negative effect of knowledge depth on alliance formation. Likewise, centralized R&D facilities will also tend to reduce the positive effect of knowledge breadth on alliance formation. The main reason is that since both broad knowledge and centralized R&D structure act to increase firms' absorptive capacity and in-house development capability, they may substitute for each other in order to reduce the costs and risks involved in alliances. We conclude that a centralized R&D structure plays a role of a "cushion" that buffers any strong influences of firm knowledge features on alliance formation.

## **THEORETICAL DEVELOPMENT AND HYPOTHESES**

### **Learning Alliances and the Firm's Technological Capability Development**

Over the past two decades there has been a global proliferation of strategic alliances. The research on understanding the motivations of alliance formation has also developed substantially in this period. Since Teece's seminal work in 1986, alliances have been regarded as one of the most effective mechanisms for firms to access specialized complementary assets (by e.g., Das & Teng, 2000). This would explain the growth in alliance formation between large incumbent companies possessing strong marketing resources and new technological firms with distinctive technological competencies (often related to a new product) designed to benefit both partners in the product commercialization process. However, in recent years, more and more researchers have suggested another important explanatory factor for the growth in strategic alliances – as platforms for organizational learning (see the review by Inkpen and Tsang, 2007). Organizational

learning theory suggests that incumbent companies attempt to learn new knowledge from their alliance partners and internalize the knowledge to build up their own internal competencies.

Although access to both complementary assets and organizational learning opportunities can drive alliance formation, they may work differently in different types of alliances. Rothaermel (2001) noted that “organizational *learning* motivates exploration alliances, while *access to complementarities* motivates exploitation alliances” (p. 690). Exploration alliances focus on the upstream stages of research and technological innovation, while exploitation alliances are market-oriented alliances in the downstream commercialization stage (Koza & Lewin, 1998). Colombo et al. (2006) confirmed Rothaermel’s argument from a large sample of Italian high-tech firms.

Since this study focuses on research alliances, we apply the *organizational learning* perspective to explain alliance formation. The literature on open innovation suggested that, in a dynamic environment, firms use a wide range of external actors as partners (including suppliers, customers, consultants and universities etc) to help them achieve and sustain innovation (Chesbrough, 2003; Laursen & Salter, 2006). Incumbent companies may pursue external knowledge acquisition to replenish their research pipelines (Higgins & Rodriguez, 2006). For instance, although Merck & Co. has long led the way in such fields as atherosclerosis and cardiovascular disease, alliances have enabled it to increase its effectiveness in the area of diabetes, obesity, neuroscience and oncology - areas where patients’ needs are projected to surge in the coming decades. Taking the example of their research in oncology, Merck & Co. allied with seven partners in the 10 years from 1995, and has announced nine oncology programs and candidates in various stages of development, mostly derived from research alliances (Demain,



2005). Such “learning alliances” can allow firms to accelerate their technological capability development while at the same time minimizing their exposure to technological uncertainties (Grant & Baden-Fuller, 2004).

Previous empirical studies on strategic alliances have analyzed many firm-specific determinants of alliance formation. They have highlighted the influences of such variables as firm size, level of R&D expenses, prior outcomes of firms’ innovative activities and firms’ social capital as accumulated from their network of prior collaborative relations (e.g., Ahuja, 2000; Belderbos et al., 2004; Colombo et al., 2006; Fritsch & Lukas, 2001; Hagedoorn, Link & Vonortas, 2000; Tether, 2002). Despite the length of the list, we need a better appreciation of the role of cumulated knowledge and its dimensions. Since learning is a cumulative and path-dependent process (Cohen & Levinthal, 1990), we expect the characteristics of a firm’s existing knowledge base to influence its future learning behavior, and so its motivation to form learning alliances. The next section explores how these characteristics operate.

### **Two Dimensions of Technological Knowledge Base: Depth and Breadth**

Describing a firm’s existing technological knowledge base is not easy, as research is a complex activity (Collins, 1985). One can think of fields of technological knowledge as mapping onto a multi-dimensional landscape (Kauffman et al., 2000). Drawing from George, Kotha and Zheng (2008), we define the depth of a technological knowledge base as its level of expertise within a technological territory. Deep knowledge allows a firm to understand casual linkage of the old components within the territory (March, 1991). It also enables the firm to make new combinations from old components, as the firm understands the limitations of existing components from repeated use. So deep understanding in one particular technological territory

not only provides expertise in solving one specific type of question, but also supports its engagement in exploring new applications of the technology (George et al., 2008). Hence we argue (like others) that knowledge depth is a critical measure that reflects both a firm's technological capability and its desire to explore new technological knowledge applications.

Breadth of technological knowledge base refers to the range of technological knowledge areas that have to be investigated to develop particular subjects (Wang & von Tunzelmann, 2000). As a measure, breadth captures the extent to which knowledge is adjacent and relevant to the research in question. A firm with a broad knowledge base is familiar with many territories on the technological knowledge landscape, and is thus capable of exploring more paths and into new regions (Kauffman et al., 2000). As with the measure of knowledge depth, studies have also found that firms with "broad" knowledge seek to improve their positions with further search (Brusoni et al., 2001), and breadth is thus another dimension of a firm's technological knowledge base that influences its exploration for new technological development, which can be seen as "orthogonal" to the depth dimension.

### **Depth of Technological Knowledge Base and Alliance Formation**

When an incumbent company's technological knowledge base in a particular area is deeper than its competitors, it is more attractive to potential partners, and hence the opportunities it has of forming alliances are increased (Ahuja, 2000). Most firms find that making their knowledge deeper is difficult, since technological uncertainties combine to raise the hurdles that firms must overcome (Mitchell & Singh, 1992), so alliances are an attractive resolution to this challenge. Just as PhD students find it attractive to work with leading scholars, so accumulated technological competence in a particular area will signal a firm as attractive to others hoping to

acquire greater knowledge through partnerships (Arora & Gambardella, 1990; Baum et al., 2000; Stuart, 1998).

From the point of view of an incumbent company with a substantial technological knowledge base, deep knowledge may exert a contradictory influence on its willingness to enter into a research alliance, and redeployment of internal resources or outright acquisitions may often seem a better option than external alliances (Rothaermel & Deeds, 2004). Since technological knowledge is a key competitive asset of a firm in R&D intensive industries, knowledge sharing may undermine competitive advantages and industry position (Conner & Prahalad, 1996; Inkpen & Tsang, 2007). Except in a few cases, such a well-endowed firm may stand to learn much less from its partners than its partners can learn from it (Ahuja, 2000; Larsson et al., 1998). Such alliances can carry an increased risk of opportunism (Williamson, 1985), and De Carolis (2003) has provided empirical evidence about the negative effects on a firm's performance of being imitated by its rivals. Moreover, innovative activities at the explorative stage may be harder to appropriate fairly between the partners because of the tacit nature of the knowledge both employed and generated during technological collaborative processes (Colombo et al., 2006; Pisano, 1990; Teece, 1986). Finally, collaboration can distract management attention (Perry-Smith & Shalley, 2003), incur alliance transaction costs (Gulati, 1995) and create isomorphic pressure for innovative firms (Dimaggio & Powell, 1983). Given the relatively limited benefits of collaboration and the relatively high costs of forming linkages, it is likely that a firm possessing a deep technological knowledge base will be less inclined to use alliances, even though its high levels of endowments may make it attractive to many partners. Based on this argument, we predict the first hypothesis:

*H1: For incumbent companies, the depth of a technological knowledge base is negatively related to the likelihood of forming research alliances.*

### **Breadth of Technological Knowledge Base and Alliance Formation**

A broad technological knowledge base supports incumbent companies when they use research alliances. First, firms with a broad technological knowledge base are better able to monitor changes in technology market and discover-recognize new opportunities that deserve exploration (George et al., 2008). Such firms are also better more able to assess the value of new technological projects offered by the prospective partners, and thus have more incentive to invest in exploring new technological opportunities with partners (Arora & Gambardella, 1990). Second, firms with a broad knowledge base may gain more from alliance learning. Cohen and Levinthal (1990) argued that knowledge broadness increases “absorptive capacity” and facilitates the innovative process by enabling organizations to make novel associations and linkages. In an industry experiencing radical technological innovation (such as biotechnology), since the new technological knowledge is dispersed in industrial networks, firms need to collaborate with others to explore the opportunities fully (Powell et al., 1996). A broad knowledge base allows the firm to build up architectural knowledge competence, integrating and linking dispersed knowledge from partner firms together into a coherent whole (Henderson & Cockburn, 1994). Finally, firms with a broad technological knowledge base may gain optimal economical performance where they can replenish their broad product lines to realize the economics of scope in the exploitation of their technologies (Piscitello, 2000; 2004).

Strategic alliance literature has provided empirical evidence supporting the value of broad technological knowledge bases in the setting up of research alliances. We note here the work of Henderson (1994) with cardiovascular drug discovery sector data, Orsenigo, Pammolli and Riccaboni (2001) with biotech industry data, Brusoni et al. (2001) with aircraft engine control systems data, and Mowery, Oxley and Silverman (1996) with cross-sectional data. All of them have found that established multi-technology R&D intensive firms are very capable of absorbing new knowledge and techniques generated outside their firm boundaries, despite the fact that major technological discontinuities and breakthroughs initially result in the growth of specialized technology producers. The mechanisms described above suggest the positive impact of breadth in an existing knowledge base on the formation of research alliances.

But do firms with a strongly broad knowledge base have diminished incentives to forming an alliance on competitive grounds? Broad knowledge is likely to be difficult to replicate because it encompasses knowledge about how components of systems interact, and tends to reside in informal communication channels and “information filters” shared by local R&D groups (Henderson & Clark, 1990; Lave & Wenger, 1991). Moreover, in a “learning race”, firms with a broad knowledge base can learn at a faster rate than their partners (Hamel, 1991), as their strong absorptive capacity increases their capabilities in building linkages between new knowledge and their existing knowledge base. Therefore, firms with a broad knowledge base have more confidence that they face lower levels of challenge that their knowledge may be replicated by their partners, and that the likely positive effects in alliances will outweigh any negative ones.

*H2: For incumbent companies, the breadth of a technological knowledge base is positively related to the likelihood of forming research alliances.*

## R&D Organizational Design and Alliance Formation

Different R&D activity locations are associated with different attitudes to technological knowledge and hence research alliances. The literature has suggested that organizational structure influences the R&D development path (Argyres, 1996; Argyres & Silverman, 2004). When R&D is *centrally* controlled and located in a single place, corporate managers are likely to be concerned with its technological evolution (Galunic & Eisenhardt, 2001). In contrast, when R&D is *decentralized* across different divisions, perhaps in different locations, the managers making alliance decisions may be more locally based, and the technological development based on the alliances may be more influenced by the specific demands of the existing context, perhaps ignoring the long term technological development goals of the wider firm (Chacar & Lieberman, 2003). Moreover, in a decentralized structure, there may be substantial coordination costs that impede optimal working, even where managers wish to pursue the collective interest. Such managers have to collect the necessary information and make a guess as to the loss of short term benefits (as potential alliance failure may lead to lower personal rewards). The difficulties of coordination are a well known problem stemming from physical separation (Kogut & Zander, 1992). Overall the literature seems to suggest that a centralized R&D organizational structure may encourage more research alliances aimed at exploring new technological opportunities (Zhang, Baden-Fuller & Mangematin, 2007).

Moving beyond the direct effect of the R&D structure on alliance formation, this study focuses on the moderating role of R&D structure on the negative/positive relationship between a firm's knowledge depth/breadth and its propensity to form alliances. First, we predict that a centralized R&D structure may alleviate the negative effect of knowledge depth on alliance

formation. As aforementioned (compared with a decentralized structure), in a centralized R&D structure the corporate managers will tend to be more alert and ready to act on new technological opportunities in the market. The literature has also suggested that centralized R&D management may be better placed to prevent leakages of important knowledge to partners during the learning process, owing to the richer alliance experience it has accumulated from managing a portfolio of alliances (Dunning, 1994) and its better internal communication (Jansen et al., 2005). Corporate managers are also more likely to be experienced in designing alliance contracts that succeed in securing innovation appropriation from learning alliances (Baden-Fuller et al., 2006; Reuer & Tong, 2005). Therefore, compared with managers in a decentralized R&D organization, corporate managers in centralized R&D organizations will have less concern about losing their technological competence and more confidence in their ability to gain from alliances, which are particular concerns when the firm has deep knowledge base. The deeper the technological knowledge base of the company, the more such concerns the managers may have, and thus the more valuable a centralized R&D structure can become in alleviating them.

*H3a: The negative relationship between an incumbent company's technological knowledge depth and its propensity to form alliances is weaker in a centralized R&D structure than in a decentralized structure.*

Second, we predict that a centralized R&D structure may also lessen the positive effect of a firm's technological knowledge breadth on its propensity to form alliances. The alliance literature has argued that a firm's in-house development capability may substitute for research alliances where there are concerns about knowledge leakage and innovation appropriation (Ahuja, 2000; Eisenhardt and Schoonhoven, 1996). Therefore, a firm that has strong in-house R&D development may have a lower incentive to use alliances. The literature has also suggested

that a centralized R&D may facilitate internal communication between researchers (Argyres & Silverman, 2004), increasing the absorptive capacity of the research team as a whole, thus contributing further towards stronger in-house development capabilities. Thus, a centralized R&D structure and a broad technological knowledge base may substitute to each other in their positive effects on alliance formation.

*H3b: The positive relationship between an incumbent company's technological knowledge breadth and its propensity to form alliances is weaker in a centralized R&D structure than in a decentralized structure.*

## METHODS

### Research Setting

The research context is that of large incumbent pharmaceutical, chemical and agro-food companies active in the biotechnology sector in Europe, Japan and North America. Three considerations motivated the choice of biotechnology sector as the setting of the study. First, this sector has been identified as one of the sectors subject to radical technological innovation (Higgins & Rodriguez, 2006; Hopkins et al., 2007), and as having a high level of research intensity making it an ideal context to analyze research activities (Katila & Ahuja, 2002). Second, biotechnology consists of a set of scientific principles and associated techniques (e.g., cell and molecular biology, genomics, proteomics and microarray technology) that provide firms with new research solutions and productive activities across several technological areas, including pharmaceuticals, chemical, agriculture, food and industrial and environmental applications (BIO, 2004). Hence, we may observe variation in the profiles of incumbent companies' technological knowledge bases in terms of their processes for integrating biotechnology with their existing



knowledge base. Third, as new technological knowledge in the biotechnology sector is dispersed among incumbent companies, new biotechnology firms (NBFs) and universities/research institutes, the sector is characterized by very high levels of alliance activity (Powell et al., 1996). The literature has found that the major motivation behind incumbent companies entering alliances with NBFs is to replenish their research pipelines (De Carolis, 2003; Hopkins et al., 2007): on average, such companies spend appropriately 14% of their R&D budget externally (Myers & Baker, 2001). Although some studies have observed the impact of alliances on innovation performance in this sector (e.g., Rothaermel, 2001; Rothaermel & Deeds, 2004), few studies have examined how and why the alliances are formed.

### **Population-Sample**

As indicated above, the research-subjects of this study are the large pharmaceutical (human therapeutics and diagnostics), chemical and agro-food companies that actively use biotechnology knowledge in their R&D. We identified a population which consists of 78 companies most active in terms of U.S. biotechnology patent applications as retrieved by the Derwent Biotechnology Abstract (DBA) database. The DBA covers all biotechnology patent applications since 1981, and provides 12 technology classes and 30 sub-classes in the biotechnology sector (see Appendix). We classified the companies into the three industries according to their SCI codes retrieved from the database of "Business & Company Resource Center". The pharmaceutical companies are those in the industry group 283 "Drugs", the agro-food companies are those in the group 287 "Agricultural Chemicals", and the chemical companies are those in the rest of the sub-groups under the SIC code 28 "Chemicals and Allied Products", which includes six sub-groups such as 281 "Industrial Inorganic Chemicals".

We believe our “population-sample” has covered most incumbent companies active in biotechnology area: as our sample includes 61 pharmaceutical companies, compared to prior major studies by Rothaermel (2001) and Rothaermel and Deeds (2004) which identified 32 large and 59 incumbent pharmaceutical firms respectively, we believe it demonstrates extensive coverage, at least in the pharmaceutical area. These 78 firms are also good representatives of incumbent companies in terms of their substantial R&D investment levels that average over \$33 millions a firm and over \$1,000 per employee.

### **Dependent Variable: New Alliances**

The dependent variable is the number of new research alliances formed by each sample firm in each year. We used the online industry database *BioCentury*, which reports and classifies biotechnological firms’ press releases, to retrieve firm alliance data from 1993 to 2002. This database offers comprehensive coverage of U.S. and foreign companies actively involved in biotech R&D, and is highly reputed and considered as reliable among industrial practitioners, although little used by academic researchers because of its high fees. We included the alliances of all a sample firm’s divisions and subsidiaries by referring to the U.S., UK and Ireland, Continental Europe, and Asia editions of *Who Owns Whom* and the *Directory of Corporate Affiliations*. 1993 was adopted as the starting year because the biotechnology industry has mushroomed since 1992, with U.S. revenues increasing from \$8 billion in 1992 to \$39.2 billion in 2003 (BIO, 2004).

We first collected data on both research and commercialization alliances (commercialization alliance becomes one control variable in data analysis), identifying 3,158 alliances and identified the alliance partner(s) and the alliance type for each. In total, 1,042

partners were involved: only two organizations joined in more than 20 alliances (27 and 24 respectively), 23 organizations joined in 10-20 alliances, 405 organizations joined in 2-9 alliances, and 612 organizations appeared only once. We cleaned the database by deleting the alliances in which both parties were in our sample list (such as the alliance between Merck and SmithKline Beecham in 1996), in order to keep only NBFs as alliance partners, so the motivations for our focal firms entering alliances were comparable. (Two large incumbents may form an alliance for purposes that are different from learning from NBF partners: such as sharing risks (Ohmae, 1989), entering new markets and technologies (Kogut, 1991) and collectively monopolizing a drug market (Porter & Fuller, 1986).) We also excluded the alliances where the partners were research institutes or universities. The remaining alliances are those between big incumbents and biotechnology companies. Cleaning the database excluded 226 alliances involving 52 focal firms and 23 alliances involving 16 universities/research institutes. It left 2,909 alliances which are comparable based on having the same (organizational learning) alliance motivation, the focus of our study.

In the second step, we separated research alliances from commercialization alliances. For the 2,552 alliances in the pharmaceutical industry, we followed Koza and Lewin's notion and Rothaermel's (2001) and Rothaermel and Deeds's (2004) empirical work in coding alliances focusing on basic research, drug discovery and pre-clinical trials as research alliances, and those targeting towards drug development, clinical trials, manufacturing, FDA approval and marketing and sales as commercialization alliances. For the 357 alliances in the chemical and agro-food industries, we followed prior literature (e.g., Mitchell & Singh, 1992) in classifying them into research alliances if they were based on research contracts or to the commercialization group if they were market-oriented (i.e., towards manufacturing, marketing or sales). We checked our

coding using second researchers to examine about 50 percent of the data points; and we found the inter-rater reliability was 0.92 - well above the conventional 0.70 cut-off point (Cohen & Cohen, 1983). Our classification of the 2,909 alliances revealed 1,550 research alliances – which became the final pool used in the data analysis, and 1,359 commercialization alliances – which were included as one control variable in the models.

### **Independent Variable: Technological Knowledge Base**

For more than a decade, scholars have used patent data as a proxy measure for a firm's stock of knowledge (e.g., De Carolis & Deeds, 1999; Hall, Jeffe & Trajtenberg, 2001; Henderson & Cockburn, 1994; Zucker, Darby & Armstrong, 2002). It was particularly true in the biotechnology sector (e.g., De Carolis, 2003; Foltz, Barham & Kim, 2002; Gittelman & Kogut, 2003; Rothaermel & Deeds, 2004). As innovative firms create temporary monopolies based on proprietary inventions protected by patents, and biotechnology is clearly a vital competence for innovation in our sample firms, biotechnology patents play a central role in their strategies (De Carolis, 2003). Since by definition a patent describes both a technical problem and a solution to that problem (Walker, 1995); analyzing patent data can provide a consistent chronology of firms' knowledge accumulation (Shan, Walker & Kogut, 1994). In our study, patents are especially appropriate to measure the features of firm knowledge, because the DBA classes allow us to classify the knowledge embodied in a patent to knowledge classes very easily, and this classification can be used to indicate both depth and breadth.

For both the depth and breadth variables, we composed data for the years 1992 through to 2001, a one year lag before the dependent variable. In approaching the use of patent data we paid considerable attention to the fact that the value of knowledge may decay over time. All of our

knowledge stock variables are calculated on a lagged basis using the “permanent inventory method” (Ahuja, 2000), which has been broadly used as a reasonable approach for the fast-moving biotechnology industry. We take a 5-year window of prior patents for each firm and each year as a method of roughly assessing the currency of a firm’s stock of knowledge, a method consistent with prior research (e.g., Ahuja, 2000; Rothaermel & Deeds, 2004). Thus the stock of knowledge for any firm in year 1992, for instance, is calculated as the sum of the patents granted to the firm in the years between 1988 and 1992 (the DBA covers data since 1981) depreciated at an annual rate of 20% (Henderson & Cockburn, 1994). The 5-year window for patenting attenuates any annual fluctuations, and thus captures a firm’s patenting propensity more accurately. In addition, it is reasonable to believe that a firm’s decision to entering alliances is based on the stock of its knowledge base (De Carolis & Deeds, 1999; Grant & Baden-Fuller, 2004).

We measured the *depth of the knowledge base* by following prior studies (e.g., Cantwell & Piscitello 2000; Patel & Pavitt, 1991; Soete, 1987). The patterns of firm technological knowledge depth can be compared on the basis of a number of different indicators. Generally, knowledge depth is a measure of concentration, and is computed in two steps. In the first step, the *Revealed Technological Advantage (RTA)* is computed as follows:

$$RTA_{it} = \left( \frac{P_{it}}{\sum_t P_{it}} \right) / \left( \frac{\sum_i P_{it}}{\sum_{it} P_{it}} \right) \quad (1)$$

where  $P$  is the number of patents held by firm  $i$  in technology class  $t$ . In other terms, Eq.(1) is the ratio of the share of firm  $i$  patents falling in technology class  $t$ , over the share of all patents falling in that technology class. This can be interpreted as an index of “comparative advantage”:

a value above unity indicates an area of relative strength and a value below unity an area of relative weakness. The definition of the index implies that its value is necessarily null or positive but is not bound by an upper limit. In the second step, we compute the coefficient of variation of all the firm's *RTA* measures:

$$Depth = \frac{\sigma_{RTA}}{\mu_{RTA}} \quad (2)$$

Eq.(2) says that the depth of the firm's knowledge base is high when the firm has developed a high relative technological advantage in one or few technology classes, whereas a vector of equal *RTA* values would produce a relatively low measure of depth<sup>1</sup>.

We measured the *breadth of knowledge base* by counting the number of technological sub-classes in *DBA* classification (see Appendix) in which the firm has been granted patents in the 5-year window.

### **Independent Variable: R&D Organizational Structure**

We followed the previous studies in measuring the *centralization* of R&D organizational structure (Argyres, 1996; Argyres & Silverman, 2004) using data collected from various sources. *The Directory of American Research and Technology* (1991-1998), which contains information on the sizes of the technical staffs of R&D laboratories and the way they are organized, was the primary information source for American sample firms. For those firms that did not release such information, we estimated the size of each lab based on the number of R&D fields listed for the lab, which is highly correlated with staff numbers (Argyres & Silverman, 2004). Enlightened by their suggested method, we categorized a firm's R&D structure as "centralized", if the ratio of

corporate to divisional researchers was greater than 1; otherwise, the structure was categorized as “decentralized”. A centralized structure is typically characterized by a relatively large corporate lab located at corporate headquarters (with single reporting lines), and relatively small (or even no) divisional labs elsewhere. By contrast, a decentralized structure has large divisional labs – often located within separately incorporated division(s) – and a relatively small central lab. These firms generally appear to have grown largely by acquisition<sup>2</sup>. Essentially, the R&D structure of all firms remained constant over the years 1991-1998 (the period covered by the directory). We checked company annual reports, and 10-K statements and company histories when available, and found similar result for the years 1999-2001<sup>3</sup>. Hence, the dummy variable *centralization* was constant over the research years 1992-2001 for each firm. We used the *Directory of European Research and Development* in various years, and a *Classified Directory of Japanese Periodicals* to collect information about the European and Japanese firms, again verifying the data from company annual reports and 10-K statements, company histories when available, and newspapers and magazines articles. The measure is principally based on the nature of the definition, as aforementioned. To check the validity of the data, we compared ours with those of Argyres and Silverman (2004). 75% of the American firms in our sample had centralized R&D, a figure that was close to the 70% ratio in their research, supporting our measurement to some extent. 83% of the European firms in our sample were categorized as having centralized R&D structures, as were 70% of the Japanese firms.

### **Control variables**

We introduced a number of control variables in line with previous researchers’ methods. The first was *R&D intensity*, measured by the ratio of R&D expenditure to the number of employees (a commonly used control). We also introduced *Firm size*, measured as the log value of the

number of its employees, as a control to reflect a firm's capability as well as its incentive to form alliances (Ahuja, 2000). Previous research provided inconsistent findings: while some studies found positive impacts (e.g., Powell & Brantley, 1991), some found no influence (e.g., Shan et al., 1994).

We controlled for national effects by adding two dummies *Europe* and *Japan*, while keeping U.S. companies as the reference group. There has been much debate about the relative efficiency and institutional structures of European versus U.S. firms in this industry, and recently the gap has been narrowed. Both industries have similar approaches to biotechnology. In contrast, Japanese firms have a different context and philosophy, and had no major biotech product approved by FDA (BIO, 2004) before 2003. There appears to be no real equivalent in Japan of the vibrant independent emerging U.S. and European biotechnology firm, and one would therefore expect Japanese firms to have fewer opportunities to form alliances, even if they had the motivation.

To control for firm heterogeneity, we included two one-period-lagged variables, one is the dependent variable, and the other is the number of *Commercialization alliances* (Heckman & Borjas, 1980).

It is believed that alliance behavior is a high market-pull process. The signal of strong market demand and growth stimulates investment by incumbent companies through partnering with NBFs. Literature has found that when equity markets are relatively hot, investors are overly optimistic about the potential of young firms (Ritter, 1984). Moreover, new firms tend to mushroom in a hot market, providing plenty of technology offers for big incumbent firms. To control for the influence of market conditions on alliance formation, we constructed a variable



called “*stock market*”. It is the average of the yearly average value of the NASDAQ Biotechnology Index (NASBOT) and NASDAQ Biotechnology Bloomberg Index (NASBOZ) stock market indexes from year 1992 to 2001.

Finally, we controlled for industrial sector influences by including a dummy variable *Pharmaceuticals*, with the other industries (such as chemicals and agricultural food) being kept as the reference group. Incumbent companies in different industries face a variety of opportunities provided by different prospective alliance partners. The existence of different IPR regimes and the role of regulators in muting or intensifying competition, are two important forces that affect the rewards available to alliance firms (Teece, 1986). In addition, the technological achievements in some sectors have higher intrinsic growth rates than in others (Park, Chen & Gallagher, 2002). For instance, pharmaceutical companies have the highest value added in the biotech industry over this period (McNamara & Baden-Fuller, 2007), with the annual number of new biotech drug approvals increasing from 7 in 1993 to 37 in 2003, and sales from US\$7 billion in 1993 to US\$28.4 billion in 2003. We predict that, in such sectors, firms are more likely to be active in forming alliances to seek supernormal economic rents.

## RESULTS

Table 1 shows the descriptive statistics and correlations for all variables, showing that the typical firm formed about two research alliances each year. We first used a Poisson regression to test the hypotheses, because our dependent variable is counts of alliances, which takes only discrete non-negative integer values (McCullagh & Nelder, 1989). Moreover, our dependent variable included a large number of zero values, where a firm formed no alliance in a particular year. A Poisson

regression can ensure that such zero values are incorporated into a model, rather than being implicitly truncated as they are in the OLS regression (Katila & Ahuja, 2002).

-----  
Insert Table 1 about here  
-----

We also applied negative binomial models to test the same models. Like Poisson regression, the negative binomial model treats the dependent variable as a count variable, but allows for a direct measure of heterogeneity (See Cameron & Trivedi, 1986). Estimating heterogeneity not only relaxes the stringent Poisson assumption of equal mean and variance in the error term, but also accounts for omitted variable bias (Walker et al., 1997). There were no substantial differences to our results, and we therefore report our results using only negative binomial models.

Table 2 depicts our main statistical results. Using the usual style of reporting, model 1 shows the effect of using the control variables without any of the independent variables; and models 2, 3 and 4 show the effect of introducing each of the independent variables *depth*, *breadth* and *centralization* separately. In each case, our independent variables add explanatory power. Model 5, with all three independent variables together, shows that the results are robust.

Hypotheses H1 and H2 argued that the two dimensions of knowledge - depth and breadth - should have opposing effects on the propensity of incumbent firms to form alliances. Depth should decrease the likelihood of making an alliance, whereas breadth should increase this likelihood. These results are supported by our regressions, which show that the knowledge

variables bear different signs (although it should be noted that the breadth effect seems to be stronger than the depth effect).

Our theorizing also predicts that the organization of R&D within the firm (centralization) should also influence the results. This theorizing stressed that centralization should appear as an interaction effect. Models 6 and 7 show how this interaction term influences each dimension of knowledge separately; and Model 8 shows how they work together. The results are even clearer than before. Not only do the depth and breadth of knowledge base continue to work in opposite directions (as forecasted in H1 and H2), but centralization moderates both effects in a manner that H3a and H3b predicted. Centralized R&D structure alleviates the negative (positive) relationship between technological knowledge depth (breadth) and alliance formation. Although the directions of the two relationships remain unchanged, their magnitude is reduced when the R&D activities are more centrally organized.

-----  
Insert Table 2 about here  
-----

To better understand the nature of the statistical results, we graphically display the interaction in Figure 1 and Figure 2, in which the vertical axis represents the new alliances. We use 1 standard deviation below and above the mean as the range for knowledge depth (breadth) and centralization, and we constrain the other variables to their mean values (Aiken & West, 1991). The figures indicate that overall knowledge depth (breadth) has negative(positive) impacts on alliance formation; but the impacts are weakened when centralization is high than low.

-----  
Insert Figure 1 and Figure 2 Here  
-----

## Controls and Robustness

Our models involving the control variables show some interesting insights. R&D intensity and firm size show significantly positive effects, although the influence of the former is both much stronger and more consistent. Market competitive dynamics (the *stock market*) also shows positive effect on alliance activity. The results support most studies in the technology management field (e.g., Arora & Gambardella, 1994; Dyer & Singh, 1998; Kinder, 2003; Quinn, 2000). The dummy coefficient for Europe does not appear to be significant, suggesting that the European context did not skew results. However, the Japanese dummy is significant and negative, as expected. Model 8 in Table 2 shows that those firms active in applying biotechnology to the pharmaceutical sector seem to be not more active in forming alliances than those firms operating in chemical, agricultural and food sectors, which justifies, to some extent, our method of mixing companies across industries. Finally the consistent and positive effects of the lagged dependent variable and the lagged variable *commercialization alliance* suggest the path-dependent nature of a firm's research alliance strategy.

Some robustness tests were undertaken. First, we were concerned that Japanese firms might not release alliance information as completely as their counterparts in Europe and U.S., but the *BioCentury* staff confirmed that Japanese firms were as active and open as their European and U.S. counterparts. We then tried first excluding the 32 Japanese firms from our sample, and second adding the product items of country dummies and the knowledge base variables into the models. In both cases the main results appeared to be substantially unchanged.

We also performed additional robustness checks on the other controls. For instance, we changed the measure of firm size from the log value of the number of employees to the log value of fixed assets, and the measure of R&D intensity from the ratio of R&D expenditure to the number of employees to the log value of R&D expenditure or the ratio of R&D expenditure to the value of fixed assets. We modified the models by excluding the lagged dependent variable, since this variable might absorb too much of the effects of firm features, and thus lead to the coefficients for the firm's knowledge base being non-significant. Finally, we controlled for all the other timing factors by adding year dummies to change random-effect models to year-fixed-effect models. None of these changes produced significant changes in the results: in sum, our results are robust to a satisfactory level.

## DISCUSSION

Alliances have been broadly recognized as a way by which firms learn new knowledge. Our objective has been to shed light on how an incumbent company's internal knowledge characteristics might influence this use of alliances. Past studies, such as Cassiman and Veugelers (2006) suggested that "internal R&D and external knowledge acquisition are complementary innovation activities" (p. 68), and highlighted the positive effects of a high level of internal R&D on firm's external knowledge acquisition. We developed this theme further suggesting that the *quantity* of internal R&D, which Cassiman and Veugelers (2006) highlighted, is only one aspect, and that the *quality* of internal R&D (depth and breadth of knowledge base) is even more important. In particular, more knowledge, when it is deep may even have a negative effect on firm's proclivity to form alliances, quite contrary to that study's results.

Second, we have some new insights into the moderating effect of R&D organizational structure. We know that, in product competition, organizational structure has a powerful moderating effect on building dynamic capabilities (e.g. Galunic & Eisenhardt, 2001), and some have also suggested that the organization of R&D effort has powerful consequences that go beyond merely internal considerations of efficiency (e.g., Birkinshaw et al., 2002; Gupta & Govindarajan, 1991). Here, our study suggests that a centralized R&D structure (with co-located R&D) may encourage corporate managers to form alliances where they can better control any leakage of their deep knowledge base. However, when the firm has very strong in-house development capabilities, as indicated by a broad knowledge base, a centralized R&D structure may also serve to reduce corporate managers' incentives to use alliances, and avoid the unnecessarily high cost and risks involved in their use. To some extent, a centralized R&D structure plays a role of a "cushion" buffering any strong influences of a firm's knowledge base features - positive or negative - on the likelihood of it forming alliances.

Third, this study improves our knowledge about how firm characteristics impact the relationship between internal knowledge base and external knowledge acquisition. Cassiman and Veugelers (2006) found that one firm characteristic – the extent to which the innovation process relies on basic R&D rather than suppliers or customers – strengthens the complementary relationship between internal R&D and external knowledge acquisition. In other words, if the firm is more reliant on basic R&D, it may benefit more from combining internal R&D with externally acquired knowledge. This finding is in line with our general proposition that firm characteristics (in this paper, R&D organizational structure) will moderate the direct effect of its internal knowledge base characteristics on its proclivity to acquire external knowledge. Therefore, like Cassiman and Veugelers (2006), our paper contributes to the literature in that it is

one of the first to examine which firm characteristics influence the relationship between its internal knowledge base and its external knowledge acquisition activities.

We also believe our paper has important consequences for the way researchers should think about measuring technological knowledge. Many papers have suggested different ways of thinking about knowledge in general, and technological knowledge in particular. Most scholars have used inputs (such as R&D spend) or surrogates (assets) to measure technological knowledge when testing the impacts of technological knowledge on alliance formation. Some (Arora & Gambardella, 1994; Dyer & Singh, 1998; Kinder, 2003; Quinn, 2000) found positive relationships, others negative relationships (Harrigan, 1985; Pisano, 1990), and some no relationships (Kleinknecht & Reijnen, 1992). A few reported more sophisticated and dynamic results (Colombo & Garrone, 1996; Mol, 2005). Our approach has been to look at outputs of the knowledge process as a metric of the firm's position in the landscape, which we believe to be superior to looking at either inputs or surrogates. As learning is a path-dependent process, we suggest this approach can be both intuitively appealing and empirically useful.

Our study offers important implications for the managers in both incumbent companies and small NBFs. For managers in incumbent companies, this study may help explain why some incumbent companies suffer from a declining pipeline (Hopkins et al., 2007; Mittra, 2007) – perhaps their managers over-estimate the risks from alliances. In biotechnology, the risks may be less than imagined as IP protection is strong (Gans et al., 2002). Such a conservative attitude by incumbent managers could be influenced by the knowledge features of the firms: they may over-value their deep and narrow knowledge base. Our work suggests that there is some value in co-

locating R&D; perhaps a centralized R&D structure may help managers overcome the perceived difficulties surrounding alliances as a form of learning.

This study also has important suggestions for the way that small NBFs should think about their partnering strategies. Alliances are vitally important for small firms generally, and for smaller biotechnology firms in particular: the fundraising from deals with big firms in 2004 was roughly US\$10 billion, almost half of the US\$22.8 billion they raised in that year (Edelson & Brown, 2005). As the executive director of global licensing at AstraZeneca (a large pharmaceutical company) said: “Pharma is keen on sourcing innovation at all stages in order to augment its own programs”. However, he differentiated the partnering activities by noting that “[The small biotech specialists] should stay reasonable with the expectation of reward for licensing out their technologies” (Haan, 2004: A6). Our results amplify his comment: we point out how the small firm may find it hard to deal with large companies who have potentially strongly competitive knowledge bases. They should look to partners with complementary assets instead, where they have better chances of a good deal (Teece, 1986).

### **Limitations and Future Studies**

Our paper has modeled competitive interactions in a technology intensive industry, looking at both firm and knowledge variables. The most obvious limitation is that the basic modeling may only be valid for industries where knowledge has clear property right protection. In some technology situations, where property right protection is poor, the tensions between collaboration and competition may play out differently.



A second limitation is our classification of depth and breadth. Knowledge is not amenable to simple classifications, and so any attempt to classify is fraught with dangers. We do not argue that our metrics are perfect here, but only that they might be better than what has gone before. We are well aware that our notion of depth and breadth might not be applicable to all technology industries, especially those based on technologies that are not subject to clear patents.

The third limitation is the way we have gone about estimating our model. When we hypothesized the impacts of competition on alliance formation, we expected to see an absence of alliances. However, we made no direct observation of the pool of alliance partners, and hence no observation either of the absence of partners. We have made an assumption that, at any time, there is a very large stock of potential partner firms available to make alliances in this field, and so the failure to measure the pool is unlikely to result in bias. However, we recognize that this might need to be checked. Ideally it would be better to identify the potential partners for each firm, and consider what happened to the rejected suitors. The industry is too numerous to have a complete population survey, but one could approach this problem by creating a population of all the firms that succeeded in having a partnership in our data-base and then tracing each firm's technology base and identifying who would be its strongest competitors, and then compare their choices of partner with those of the potential competitor set. This would clearly be no easy task: there would be more than 600 firms in the sample, coupled with year variables, and we would need to identify the firms individually and collect data on their patent position for each year, in each patent class, which would result in some 6,000 firm-year observations. We suggest that our failure to undertake such work is not likely to have resulted in bias, and is best left for another research project.

One direction for future work is to investigate alliance formation from the perceptions of the managers involved. Porac, Thomas and Baden-Fuller (1989) have pointed out that competition is as much a cognitive phenomenon as one driven by economic positions: in the Scottish Knitwear industry, firms were more oriented to competing with like firms than dealing with the tangible threats of Italian producers such as Benetton. Thus, the ability of organizations to respond to a competitive threat or a collaboration opportunity is likely to depend on their top managers' perceptions. The future research in this line could use surveys to measure such cognitive variables as managers' risk-aversion proclivity, confidence and sensitivity to change, and either position these variables as mediators between knowledge feature variables and alliance decisions, or test the moderating role of the cognitive variables to explain why managers in some companies tend to form more alliances than those in the other companies with similar knowledge features.

Finally, Lucia Piscitello and her colleagues (Piscitello, 2000; 2004; Cantwell & Piscitello, 2000; 2005) have provided distinctive concepts of technological breadth (upstream inputs) and product breadth (downstream outputs). In particular, she has argued (2000) that a high level of interconnection between the two constructs increases the company's corporate coherence and eventually its economic performance. Taking this direction, future research could investigate how product breadth, rather than technological breadth, might influence alliance formation – or, indeed, how the interaction of the two constructs might jointly influence alliance formation.

## **CONCLUSION**

In the 21<sup>st</sup> century, knowledge management is the core competency for many companies, and how to learn in a fast, safe and cheap way is a critical question for large incumbent firms. This

study shows that the *quality* of firm knowledge base, as measured by depth and breadth, has sophisticated influences on technology collaboration. When a firm has broad knowledge that is centralized in a single location, it seems that it can overcome the obstacles of knowledge leakage and use alliances to strengthen its position even further; in contrast, a firm that has deep knowledge base that is decentralized in many locations may feel vulnerable to alliances and have to find other ways to sustain their advantages.

NOTES:

1. We also used another method to calculate *depth* by dividing “knowledge capital” by the breadth of knowledge base. The variable “knowledge capital” is calculated by counting the number of patents granted to the firm weighted by the number of technological sub-classes each patent covered. It measures the average effort a firm makes in each technological class. We tested the hypotheses with this measure, and the results showed no substantial differences from those using the measure reported in the text.
2. Argyres and Silverman (2004) categorized R&D organizational structure into 5 levels: centralized, centralized hybrid, balanced hybrid, decentralized hybrid and decentralized. We adopted only 2 levels, because of the lack of information at the same level of detail for the European and Japanese firms.
3. Of the 78 companies, only Abbott substantially changed their R&D organizational structures during 1999-2001. Abbott formed the Global Pharmaceutical Research and Development (GPRD) organization, unifying all research and development at Abbott into a single in year 2000 ([http://www.abbott.com/GPRD/GPRD\\_AboutUs.htm](http://www.abbott.com/GPRD/GPRD_AboutUs.htm)), and its basic research alliance increased from average 3/year to 11 in year 2001. We therefore treated “centralization” for Abbott in year 2000 and 2001 as missing data in the regressions.

## References

- Ahuja, G. (2000). 'The duality of collaboration: inducements and opportunities in the formation of interfirm linkages'. *Strategic Management Journal*, **21**, 317-343.
- Aiken, L.S. and West, S.G. (1991). *Multiple Regression: Testing and Interpreting Interactions*. Thousand Oaks: Sage.
- Ambos, T., Makela, K., Birkinshaw, J. and D'Este, P. (2008). 'When does university research get commercialised? Creating ambidexterity in research institutions'. *Journal of Management Studies*, **45**(8), 1424-1447.
- Argyres, N. S. (1996). 'Capabilities, technological diversification and divisionalization'. *Strategic Management Journal*, **17** (5), 395-410.
- Argyres, N. S. and Silverman, B. S. (2004). 'R&D, organization structure, and the development of corporate technological knowledge'. *Strategic Management Journal*, **25**, 929-958.
- Arora, A. and Gambardella, A. (1990). 'Complementarities and external linkages: The strategies of the large firms in biotechnology'. *The Journal of Industrial Economics*, **37**, 361-379.
- Arora, A. and Gambardella, A. (1994). 'Evaluating technological information and utilizing it: Scientific knowledge, technological capability, and external linkages in biotechnology'. *Journal of Economic Behavior and Organization*, **24**, 91-114.
- Baden-Fuller, C., Dean, A., McNamara, P., and Hilliard, B. (2006). 'Raising the returns to venture finance'. *Journal of Business Venturing*, **21**, 265-285.
- Baum, J. A., Calabrese, T., and Silverman, B. (2000). 'Don't go it alone: Alliance network composition and startups' performance in Canadian biotechnology'. *Strategic Management Journal*, **21**, 267-294.
- Belderbos, R., Carreeb. M., and Lokshin, B. (2004). 'Cooperative R&D and firm performance'. *Research Policy*, **33**(10), 1477-1492.
- BIO. (2004). *BIO's Editors' and Reporters' Guide to Biotechnology*. [www.bio.org](http://www.bio.org): Biotechnology Industry Organization.
- Birkinshaw, J., Nobel, R., and Ridderstrale, J. (2002). 'Knowledge as a contingency variable: Do the characteristics of knowledge predict organization structure'. *Organization Science*, **13**, 274-289.
- Brusoni, S., Prencipe, A., and Pavitt, K. (2001). 'Knowledge specialization, organizational coupling, and the boundaries of the firm: Why do firms know more than they make?' *Administrative Science Quarterly*, **46**, 597-621.
- Cameron, A. C. and Trivedi, P. K. (1986). 'Econometric Models Based on Count Data: Comparisons and Application of Some Estimators and Tests'. *Journal of Applied Econometrics*, **1**, 29-53.
- Cantwell, J. and Piscitello, L. (2005). 'Recent location of foreign-owned research and development activities by large multinational corporations in the European regions: The role of spillovers and externalities'. *Regional Studies*, **39**(1), 1-16.
- Cassiman, B. and Veugelers, R. (2006). 'In search of complementarity in the innovation strategy:

- Internal R&D and external knowledge acquisition'. *Management Science*, **52** (1), 68-82.
- Chacar, A. S. and Lieberman, M. B. (2003). 'Organizing for technological innovation in the U.S. pharmaceutical industry'. *Advances in Strategic Management*, **20**, 299-322.
- Chesbrough, H. W. (2003). *Open Innovation: The New Imperative for Creating and Profiting from Technology*. Boston, MA: Harvard Business Press.
- Cohen, J. and Cohen, P. (1983). *Applied Multiple Regression/Correlation Analysis for The Behavioral Sciences*. Hillsdale, NJ: Lawrence Erlbaum Associates, Inc.
- Cohen, W. M. and Levinthal, D. A. (1990). 'Absorptive capability: A new perspective on learning innovation'. *Administrative Science Quarterly*, **35**, 128-152.
- Collins, H. M. (1985). *Changing Order: Replication and Induction in Scientific Practice*. Beverley Hills London: Sage.
- Colombo, M. G. and Garrone, P. (1996). 'Technological cooperative agreements and firm's R&D intensity: A note on causality relations'. *Research Policy*, **25**(6), 923-932.
- Colombo, M. G., Grillia, L., and Piva, E. (2006). 'In search of complementary assets: The determinants of alliance formation of high-tech start-ups'. *Research Policy*, **35**(8), 1166-1199 .
- Conner, K. R. and Prahalad, C. K. (1996). 'A resource-based theory of the firm: Knowledge versus opportunism'. *Organization Science*, **7**, 477-501.
- Das, T. K. and Teng, B. S. (2000). 'A Resource-Based theory of strategic alliances'. *Journal of Management*, **26**, 31-61.
- De Carolis, D. M. (2003). 'Competencies and imitability in the pharmaceutical industry: An Analysis of their Relationship with firm performance'. *Journal of Management*, **29**(1), 27-50.
- De Carolis, D. M. and Deeds, D. (1999). 'The impact of stocks and flows of organizational knowledge on firm performance: an empirical investigation of the biotechnology industry'. *Strategic Management Journal*, **20**(10), 953-968.
- Demain, P. (2005). Building new alliances: Drug company in strong position and bullish about investment in science. [www.merck.com/licensing](http://www.merck.com/licensing) (accessed on Feb 18, 2006).
- Dhanaraj, S., Lyles, M. A., Steensma, K., and Tihanyi, L. (2004). 'Managing tacit and explicit knowledge transfer in IJVs: The role of relational embeddedness and the impact on performance'. *Journal of International Business Studies*, **35**(5), 428-442.
- DiMaggio, P. J. and Powell, W. W. (1983). 'The iron cage revisited: Institutional isomorphism and collective rationality in organizational fields'. *American Sociological Review*, **48**, 147-160.
- Dunning, J. H. (1994). 'Multinational enterprises and the globalization of innovatory capacity'. *Research Policy*, **23**, 67-88.
- Dyer, J. H. and Nobeoka, K. (2000). 'Creating and managing a high performance knowledge-sharing network: the Toyota case'. *Strategic Management Journal*, **21**(3), 345-368.
- Dyer, J. H. and Singh, H. (1998). 'The relational view: Cooperative strategy and sources of interorganizational competitive advantage'. *Academy of Management Review*, **23**(4), 660-679.
- Edelson, S. and Brown, S. (2005). Go figure. *BioCentury: The Bernstein Report on BioBusiness*, 13(1), A19-A23.

- Eisenhardt, K. and Schoonhoven, C. B. (1996). 'Resource-based view of strategic alliance formation: Strategic and social effects in entrepreneurial firms'. *Organization Science*, **7**(2), 136-150.
- Ettlie, J. E. and Pavlou, P. A. (2006). 'Technology-based new product development partnerships'. *Decision Science*, **37**(2), 117-147.
- Foltz, J., Barham, B. and Kim, K. (2000). 'Universities and Agricultural biotechnology patent production'. *Agribusiness*, **16**, 82-95.
- Fredrickson, J. W. (1986). 'The strategic decision process and organizational structure'. *Academy of Management Review*, **11**(2): 280-297.
- Fritsch, M. and Lukas, R. (2001). 'Who cooperates on R&D?'. *Research Policy*, **30**(2), 297-312.
- Galunic, D. C. and Eisenhardt, K. M. (2001). 'Architectural innovation and modular corporate forms'. *Academy of Management Journal*, **44**, 1229-1250.
- Gans, J. S., Hsu, D.H., and Stern, S. (2002). 'When does start-up innovation spur the gale of creative destruction?'. *RAND Journal of Economics*, **33**, 71-86.
- George, G., Kotha, R. R. and Zheng, Y. (2008). 'Entry into insular domains: A longitudinal study of knowledge structuration and innovation in biotechnology firms'. *Journal of Management Studies*, **45**(8), 1448-1474.
- Gittelman, M. and Kogut, B. (2003). 'Does good science lead to valuable knowledge? Biotechnology firms and the evolutionary logic of citation patterns'. *Management Science*, **49**(4), 366-382.
- Grant, R. and Baden-Fuller, C. (2004). 'A knowledge access theory of strategic alliances'. *Journal of Management Studies*, **41**, 61-84.
- Gulati, R. (1995). 'Does Familiarity Breed Trust? The Implications of Repeated Ties for Contractual Choice in Alliances'. *Academy of Management Journal*, **35**, 85-112.
- Gupta A. and Govindarajan, V. (1991). 'Knowledge flows and the structure of controls within multinational corporations'. *Academy of Management Review*, **16**, 768-792.
- Haan, K. (2004). Whetting pharma's appetite. *BioCentury: The Bernstein Report on BioBusiness*, 12(12), A7-A9.
- Hagedoorn, J., Link, A. N. and Vonortas, N. S. (2000). 'Research partnerships'. *Research Policy*, **29**(4-5), 567-586.
- Hall, B., Jaffe, A., and Trajtenberg, M. (2001). *The NBER Patent Citation Data File: Lessons, Insights, and Methodological Tools*. Working paper, No. 8498, National Bureau of Economic Research
- Hamel, G. (1991). 'Competition for competence and inter-partner learning within international strategic alliances'. *Strategic Management Journal*, **12** (Winter special issue), 83-103.
- Harrigan, K. R. (1985). *Strategies for Joint Ventures*. Lexington, MA: Lexington Books.
- Heckman, J. and Borjas, G. (1980). 'Does unemployment cause future unemployment?'. *Economica*, **47**, 247-283.
- Henderson, R. (1994). 'The evolution of integrative capabilities: innovation in cardiovascular

- drug discovery'. *Industrial and Corporate Change*, **33**, 607-630.
- Henderson, R. M. and Clark, K. B. (1990). 'Architectural innovation: The reconfiguration of existing product technologies and the failure of established firms'. *Administrative Science Quarterly*, **35**, 930.
- Henderson R. and Cockburn, I. (1994). 'Measuring competence? Exploring firm effects in pharmaceutical research'. *Strategic Management Journal*, **15**(Winter Special Issue), 63-84.
- Higgins, M. J. and Rodriguez, D. (2006). 'The outsourcing of R&D through acquisitions in the pharmaceutical industry'. *Journal of Financial Economics*, **80**(2), 351-383.
- Hopkins, M. M., Martin, P. A., Nightingale, P., Kraft, A. and Mahdi, S. (2007). 'The myth of the biotech revolution: An assessment of technological, clinical and organisational change'. *Research Policy*, **36** (4), 566-589 .
- Inkpen, A. C. and Tsang, E. (2007). 'Learning and Strategic Alliances' in *The Academy of Management Annals*, **1**, 479-511.
- Inkpen, A. C. and Wang, P. (2006). 'An examination of collaboration and knowledge transfer: China-Singapore Suzhou Industrial Park'. *Journal of Management Studies*, **43**(4), 779-811.
- Ireland, R. D., Hitt, M. A., and Vaidyanath, D. (2002). Alliance Management as a source of competitive advantage. *Journal of Management*, 28(3), 413-446.
- Jansen, J., van den Bosch, F., and Volberda, H. (2005). 'Managing potential and realized absorptive capacity: How do organizational antecedents matter'. *Academy of Management Journal*, **48**, 999-1015.
- Katila, R. and Ahuja, G. (2002). 'Something old, something new: A longitudinal study of search behavior and new product introduction'. *Academy of Management Journal*, **45**(6), 1183-1194.
- Kauffman, S., Lobo, J., and Macready, W. G. (2000). 'Optimal search on a technology landscape'. *Journal of Economic Behavior & Organization*, **43**, 141-166.
- Kinder, T. (2003). 'Go with the flow-a conceptual framework for supply relations in the era of the extended enterprise'. *Research Policy*, **32**(3), 503-523.
- Kleinknecht, A. and Reijnen, J. O. N. (1992). 'Why do firms cooperate on R&D? An empirical study'. *Research Policy*, **21**, 347-360.
- Kogut, B. (1991). 'Joint ventures and the option to expand and acquire'. *Management Science*, **37**(1), 19-33.
- Kogut, B. and Zenger, U. (1992). 'Knowledge of the firm, combinative capabilities, and the replication of technology'. *Organization Science*, **3**, 383-397.
- Koza, M. P. and Lewin, A. Y. (1998). 'The co-evolution of strategic alliances'. *Organization Science*, **9**, 255-264.
- Lane, P. J. and Lubatkin, M. (1998). 'Relative absorptive capacity and interorganizational learning'. *Strategic Management Journal*, **19** (5), 461-477.
- Larsson, R., Bengtsson, L., Hendricksson, K., and Sparks, J. (1998). 'The interorganizational learning dilemma: Collective knowledge development in strategic alliances'. *Organization Science*, **9**, 285-296.



- Laursen, K. and Salter, A. (2006). 'Open for innovation: the role of openness in explaining innovation performance among U.K. manufacturing firms'. *Strategic Management Journal*, **27**(2), 131-150.
- Lave, J. and Wenger, E. (1991). *Situated Learning: Legitimate Peripheral Participation*. Cambridge: Cambridge University Press.
- March, J. G. (1991). 'Exploration and exploitation in organizational learning'. *Organization Science*, **2**(1), 71-87.
- McCullagh, P. and Nelder, J. (1989). *Generalized Linear Models*. New York: Chapman & Hall.
- McNamara, P. and Baden-Fuller, C. (2007). 'Shareholder returns and the exploration-exploitation dilemma: R&D announcements by biotechnology firms'. *Research Policy*, **36**(4), 548-565.
- Mitchell, W. and Singh, K. (1992). '“Incumbents” use of pre-entry alliances before expansion into new technical subfields of an industry'. *Journal of Economic Behavior and Organization*, **18**(3), 347-372.
- Mitra, J. (2007). 'Life science innovation and the restructuring of the pharmaceutical industry: Merger, acquisition and strategic alliance behaviour of large firms'. *Technology Analysis & Strategic Management*, **19**(3), 279-301.
- Mol, M. J. (2005). 'Does being R&D intensive still discourage outsourcing? Evidence from Dutch manufacturing'. *Research Policy*, **34**(4), 571-582.
- Mowery, D., Oxley, J., and Silverman, B. (1996). 'Strategic alliances and interfirm knowledge transfer'. *Strategic Management Journal*, **30**, 77-92.
- Myers, S. and Baker, A. (2001). 'Drug discovery—an operating model for a new era'. *Nature Biotechnology*, **19**, 727-730.
- Nielsen, B. B. and S. Nielsen (2009). 'Learning and innovation in international strategic alliances: An empirical test of the role of trust and tacitness'. *Journal of Management Studies*, **46**(6), 1031-1056.
- Orsenigo, L., Pammolli, F., and Riccaboni, M. (2001). 'Technological change and network dynamics: Lessons from the pharmaceutical industry'. *Research Policy*, **30**, 485-508.
- Pangarkar, N. (2009). 'Do firms learn from alliance terminations? An empirical examination'. *Journal of Management Studies*, **46**(6), 982-1004.
- Park, S. H., Chen, R., and Gallagher, S. (2002). 'Firm resources as moderators of the relationship between market growth and strategic alliances in semiconductor start-ups'. *Academy of Management Journal*, **45**, 527-545.
- Patel, P. and Pavitt, K. (1991). 'Large firms in the production of the world's technology: An important case of "non-globalisation" '. *Journal of International Business Studies*, **22**(1), 1-21.
- Perry-Smith, J. E. and Shalley, C. E. (2003). 'The social side of creativity: A static and dynamic social network perspective'. *Academy of Management Review*, **28**(1), 89-107.
- Pisano, G. P. (1990). 'The R&D boundaries of the firm: An empirical analysis'. *Administrative Science Quarterly*, **35**, 153-176.

- Piscitello, L. (2000). 'Relatedness and coherence in technological and product diversification of the world's largest firms'. *Structural Change and Economic Dynamics*, **11**, 295–315.
- Piscitello, L. (2004). 'Corporate diversification, coherence and economic performance'. *Industrial and Corporate Change*, **13**(5), 757-787.
- Porac, J. F., Thomas, H., and Baden-Fuller, C. (1989). 'Competitive groups as cognitive communities: The case of Scottish knitwear manufacturers'. *Journal of Management Studies*, **26**(4), 397-416.
- Porter, M. E. and Fuller, M. B. (1986). 'Coalitions and global strategy', in M. E. Porter (Ed.), *Competition in Global Industries*. Boston, MA.: Harvard Business School Press.
- Powell, W. W. and Brantley, P. (1992). 'Competitive cooperation in biotechnology: Learning through networks', in Nahria, N. and Eccles, R. (Eds.), *Networks and Organizations: Structure, Form and Action*. Boston, MA: Harvard Business School Press.
- Powell, W. W., Koput, K. W., and Smith-Doerr, L. (1996). 'Interorganizational collaboration and the locus of innovation: Networks of learning in biotechnology'. *Administrative Science Quarterly*, **41**, 116-145.
- Quinn, J. B. (2000). 'Outsourcing innovation: The new engine of growth'. *Sloan Management Review*, **41**(4), 13-28.
- Reuer, J. J. and Tong, T. W. (2005). 'Real options in international joint ventures'. *Journal of Management*, **31**, 403-423.
- Ritter, J. R. (1984). 'The "hot issue" market of 1980'. *Journal of Business*, **57**(2), 215-241.
- Rothaermel, F. (2001). 'Incumbent's advantage through exploring complementary Assets via interfirm cooperation'. *Strategic Management Journal*, **22**, 687-699.
- Rothaermel, F. and Boeker, W. (2007). 'Old technology meets new technology: Complementarities, similarities, and alliance formation'. *Strategic Management Journal*, **29**, 47-77.
- Rothaermel, F. and Deeds, D. (2004). 'Exploration and exploitation alliances in biotechnology: a system of new product development'. *Strategic Management Journal*, **25**, 201-221.
- Rothaermel, F. and Deeds, D. L. (2006). 'Alliance type, alliance experience and alliance management capability in high-technology ventures'. *Journal of Management*, **21**(4), 429-460.
- Shan, W., Walker, G., and Kogut, B. (1994). 'Interfirm cooperation and startup innovation in the biotechnology industry'. *Strategic Management Journal*, **15**, 387-394.
- Siggelkow, N. and Levinthal, D. A. (2003). 'Temporarily divide to conquer: Centralized, decentralized, and reintegrated organizational approaches to exploration and adaptation'. *Organization Science*, **14**(6), 650-669.
- Siggelkow, N. and Rivkin, J. W. (2005). 'Speed and search: Designing organizations for turbulence and complexity'. *Organization Science*, **16**(2), 101-122.
- Simonin, B. L. (1999). 'Ambiguity and the process of knowledge transfer in strategic alliances'. *Strategic Management Journal*, **20**(4), 595-623.
- Soete, L. (1987). 'The impact of technological innovation on international trade patterns: the

- evidence reconsidered'. *Research Policy*, **16**(2), 101-130.
- Stuart, T. (1998). 'Network positions and propensities to collaborate: An investigation of alliances formation in a high-technology industry'. *Administrative Science Quarterly*, **43**, 668-698.
- Teece, D. J. (1986). 'Profiting from technological innovation: Implications for integration, collaboration, licensing, and public policy'. *Research Policy*, **15**, 285-305.
- Tether, B. S. (2002). 'Who co-operates for innovation, and why: An empirical analysis'. *Research Policy*, **31**(6), 947-967.
- Tsang, E. (2000). 'Transaction cost and resource-based explanations of joint ventures: A comparison and synthesis'. *Organization Science*, **21**(1), 215-242.
- Volberda, H. W. (1996). 'Toward the flexible form: How to remain vital in hypercompetitive environments'. *Organization Science*, **7**(4), 359-374.
- Walker, R. (1995). *Patents as Scientific and Technical Literature*. Metuchen, NJ: Scarecrow Press.
- Walker, G., Kogut, B, and Shan, W. (1997). 'Social capital, structural holes and the formation of an industry network'. *Organization Science*, **8**(2),109-125.
- Wang, Q. and von Tunzelmann, G. N. (2000). 'Complexity and the functions of the firm: Breadth and depth'. *Research Policy*, **29**, 805-818.
- Williamson, O. E. (1985). *The Economic Institutions of Capitalism*. New York: Free Press.
- Zhang, J., Baden-Fuller, C., & Mangematin, V. (2007). 'Technological knowledge base, R&D organization structure and alliance formation: Evidence from the biopharmaceutical industry', *Research Policy*, **36**(4): 515-528.
- Zucker, L. G., Darby, M. R., and Armstrong, J. S. (2002). 'Commercializing knowledge: University science, knowledge capture, and firm performance in biotechnology'. *Management Science*, **48**, 138-153.

**TABLE 1:**  
**Descriptive Analysis and Correlation Matrix**

	1	2	3	4	5	6	7	8	9	10	11	12
1. Research alliances <sub>t</sub>	1.000											
2. R&D intensity (1,000US\$)	-0.155*	1.000										
3. Size	0.305*	-0.200*	1.000									
4. Europe	0.151*	-0.212*	0.484*	1.000								
5. Japan	-0.364*	0.556*	-0.212*	-0.396*	1.000							
6. Pharmaceuticals	0.178*	0.217*	0.265*	0.095*	-0.129*	1.000						
7. Research alliances <sub>t-1</sub>	0.727*	-0.204*	0.306*	-0.386*	0.141*	0.169*	1.000					
8. Commercial alliances <sub>t-1</sub>	0.429*	-0.120	0.319*	-0.217*	0.203*	0.176*	0.398*	1.000				
9. Stock market	0.175*	0.219*	0.011	0.000	0.000	0.211*	0.194*	0.225*	1.000			
10. Depth	-0.090*	0.041	0.029	0.020	0.089*	0.095*	-0.101	-0.086	0.079	1.000		
11. Breadth	0.208*	0.004	0.461*	0.188*	0.227*	0.086*	0.205*	0.268*	-0.049	0.149*	1.000	
12. Centralization	0.176*	0.143*	0.137*	-0.166*	0.052	0.062	0.172*	0.069	0.000	-0.016	.160*	1.000
Mean	1.815	1.064	9.186	0.151	0.445	0.813	1.595	1.139	0.266	1.056	15.438	0.788
Std. Dev.	3.113	2.069	1.817	0.358	0.497	0.400	3.218	1.980	0.184	0.383	5.632	0.409
Minimum	0.000	0.009	2.710	0.000	0.000	0.000	0.000	0.000	0.091	0.100	2.000	0.000
Maximum	20.00	14.045	12.64	1.000	1.000	1.000	20.00	18.00	0.656	3.600	9.000	1.000

N=648


\*  $p < 0.01$

**TABLE 2:**  
**Negative Binomial Regression of the Impact of Firm Knowledge Base, R&D Organizational Structure on the Number of New Research Alliances Formation**  
<sup>a</sup>


	Model 1	Model 2	Model 3	Model 4	Model 5	Model 6	Model 7	Model 8
<i>Controls</i>								
R&D intensity <sub>t-1</sub>	0.198*** [0.048]	0.199*** [0.047]	0.201*** [0.044]	0.196*** [0.045]	0.196*** [0.044]	0.203*** [0.042]	0.210*** [0.041]	0.210*** [0.046]
Size <sub>t-1</sub>	0.141* [0.059]	0.143* [0.055]	0.144* [0.052]	0.129* [0.054]	0.120* [0.055]	0.142* [0.051]	0.139* [0.057]	0.122* [0.051]
Europe	-0.198 [0.294]	-0.194 [0.280]	-0.161 [0.272]	-0.176 [0.274]	-0.155 [0.279]	-0.139 [0.271]	-0.180 [0.277]	-0.138 [0.263]
Japan	-2.061*** [0.298]	-2.060*** [0.284]	-2.132*** [0.273]	-1.997*** [0.284]	-1.993*** [0.283]	-2.022*** [0.276]	-2.011*** [0.281]	-2.065*** [0.243]
Y <sub>t-1</sub>	0.048*** [0.007]	0.047*** [0.006]	0.047*** [0.006]	0.045*** [0.006]	0.050*** [0.007]	0.045*** [0.007]	0.046*** [0.008]	0.047*** [0.007]
Commercialization alliance <sub>t-1</sub>	0.013* [0.005]	0.013* [0.006]	0.013* [0.006]	0.013* [0.005]	0.012* [0.006]	0.013* [0.006]	0.013* [0.006]	0.012* [0.007]
Stock market <sub>t-1</sub>	0.617** [0.216]	0.617** [0.217]	0.619** [0.218]	0.616** [0.215]	0.615** [0.216]	0.616** [0.216]	0.616** [0.217]	0.617** [0.212]
Pharmaceuticals	0.539* [0.259]	0.544* [0.245]	0.497* [0.240]	0.534* [0.244]	0.496* [0.243]	0.476+ [0.241]	0.465+ [0.243]	0.550 [0.242]
<i>Firm knowledge base features</i>								
Depth <sub>t-1</sub>		-0.338* [0.164]			-0.325* [0.161]	-0.331* [0.159]	-0.288* [0.147]	-0.330* [0.161]
Breadth <sub>t-1</sub>			0.076*** [0.015]		0.075*** [0.015]	0.072*** [0.013]	0.077*** [0.014]	0.083*** [0.013]
Centralization				0.916*** [0.281]	0.874*** [0.274]	0.903*** [0.278]	0.885*** [0.276]	0.895*** [0.279]
Depth <sub>t-1</sub> * Centralization						0.181** [0.061]		0.182** [0.061]
Breadth <sub>t-1</sub> * Centralization							-0.079** [0.026]	-0.076** [0.028]
No. of firms	78	78	78	78	78	78	78	78
No. of observation	648	648	648	648	648	648	648	648
Log-likelihood	-923.39	-915.32	-913.09	-910.33	-896.99	-879.05	-876.72	-858.34

<sup>a</sup> S.E. in brackets.  
+  $p < 0.10$ , \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ .

**FIGURE 1:**  
**Split-plot Analysis of the Interaction Effects of R&D Centralization and Knowledge Depth on Alliance Formation**



**FIGURE 2:**  
**Split-plot Analysis of the Interaction Effects of R&D Centralization and Knowledge Breadth on Alliance Formation**



**APPENDIX I:  
Derwent Biotechnology Abstracts Technological Classes and Sub-classes**

<b>DBA Technology Classes</b>	<b>DBA Technology Sub-Classes</b>
A-Genetic-Engineering-and-Fermentation	A1-Nucleic-Acid-Technology
	A2-Fermentation
B-Engineering	B1-Biochemical-Engineering
C-Analysis	C1-Sensors-and-Analysis
D-Pharmaceuticals	D1-Antibiotics
	D2-Hormones
	D3-Peptides-and-Proteins
	D4-Vaccines
	D5-Other-Pharmaceuticals
	D6-Antibodies
	D7-Clinical-Genetic-Techniques
E-Agriculture	E1-Biological-Control-Agents
	E2-Plant-Genetic-Engineering
	E3-Pesticides
	E4-In-Vitro-Propagation
	E5-Agricultural,-Other
F-Food	F1-Food-and-Food-Additives
G-Fuels,-Mining-and-Metal-Recovery	G1-Biofuels-and-Solvents
	G2-Mining-and-Metal-Recovery
H-Other-Chemicals	H1-Polymers
	H2-Chiral-Compounds
	H3-Miscellaneous-Compounds
	H4-Polyunsaturates
J-Cell-Culture	J1-Animal-Cell-Culture
	J2-Plant-Cell-Culture
K-Biocatalysis	K1-Isolation-and-Characterization
	K2-Application
L-Purification	L1-Downstream-Processing
M-Waste-Disposal-and-the-Environment	M1-Industrial-Waste-Disposal
	M2-Environmental-Biotechnology